|
| | PD 166793 Basic information |
| Product Name: | PD 166793 | | Synonyms: | PD 166793;(S)-2-(4'-bromobiphenyl-4-ylsulfonamido)-3-methylbutanoic acid;N-[(4'-Bromo[1,1'-biphenyl]-4-yl)sulfonyl]-L-valine;(S)-2-(4'-Bromo-[1,1'-biphenyl]-4-ylsulfonamido)-3-methylbutanoic acid;MMP-2/MMP-3 Inhibitor;L-Valine, N-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-;(2S)-2-[[4-(4-bromophenyl)phenyl]sulfonylamino]-3-methylbutanoicaci;PD 166793 USP/EP/BP | | CAS: | 199850-67-4 | | MF: | C17H18BrNO4S | | MW: | 412.3 | | EINECS: | | | Product Categories: | Angiogenesis and Metastasis;Protease inhibitor | | Mol File: | 199850-67-4.mol |  |
| | PD 166793 Chemical Properties |
| Melting point | 192-193℃ | | density | 1.457 | | storage temp. | Sealed in dry,2-8°C | | solubility | DMF: 50 mg/ml; DMSO: 50 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml; Ethanol: 10 mg/ml | | form | A crystalline solid |
| | PD 166793 Usage And Synthesis |
| Uses | PD 166793 is a matrix metalloproteinase inhibitor in the treatment of inflammatory pathological occurrences involving blood pressure and the cardiac system. | | General Description | A cell-permeable biphenylsulfonylvaline compound that acts as a potent inhibitor against MMP-2, -3, and -13 (IC50 = 47, 12, and 8 nM, respectively) and a weaker inhibitor against AMP deaminase (20% inhibition at 0.1 μM), MMP-1, -7, -9, and -14 (IC50 = 6.1, 7.2, 7.9, and 0.24 μM, respectively). Shown to offer therapeutic benefits in vivo in various animal models of heart failure and diabetes. | | Biological Activity | Broad spectrum matrix metalloprotease (MMP) inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC 50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure. | | Biochem/physiol Actions | Cell permeable: yes | | storage | Desiccate at +4°C |
| | PD 166793 Preparation Products And Raw materials |
|
